IM-1617
Undisclosed Solid Tumor Target(s)
PreclinicalADC program
Key Facts
About Immunome
Immunome is a clinical-stage biotech dedicated to improving outcomes for cancer patients through a portfolio of targeted therapies, primarily centered on antibody-drug conjugates (ADCs). The company's most advanced asset is varegacestat, a gamma secretase inhibitor in Phase 3 for desmoid tumors, complemented by earlier-stage ADC and radioligand programs. Under the leadership of CEO Clay Siegall, co-founder of Seagen, Immunome leverages significant ADC expertise to pursue differentiated targets and optimize therapeutic candidates for efficacy and tolerability.
View full company profile